Zevra Therapeutics announced that the European Medicines Agency's CHMP issued a negative opinion on its marketing application for arimoclomol, a treatment for Niemann-Pick disease type C (NPC). The company plans to request a re-examination and continue supporting patient access through its global Expanded Access Program. Despite the setback, Zevra remains confident in arimoclomol's potential and is committed to bringing the therapy to patients in Europe. The decision highlights ongoing challenges in regulatory approval for rare disease treatments but underscores Zevra's dedication to the NPC community.
Peter Kendall has stepped down as Interim CEO of ARCpoint Inc. after completing his 90-day mandate to assess the company's business model, technology platform, and strategic direction. He provided recommendations to the Board, which is now evaluating...
Oportun Financial Corporation has been recognized on CNBC's World's Top Fintech Companies 2026 list for the third consecutive year, highlighting its impact in the Wealth Technology category. The company is praised for its technology-driven tools that...
Robbins Geller Rudman & Dowd LLP has filed a class action lawsuit against PROCEPT BioRobotics Corporation and its executives, accusing them of misleading investors by inflating sales figures through an undisclosed discount program that caused excess ...
Bitcoin dropped about 14% in Q2 2026, closing near $58,544, yet its one-year realized volatility remained low at 42%, close to multi-year lows. This suggests selling was orderly, not panic-driven, reflecting a more mature market compared to past shar...
Sui (SUI) experienced a 5% price drop in 24 hours despite Coinbase enabling direct staking with rewards credited to users. This unexpected sell-off came amid a broader crypto market downturn, with Bitcoin and Ethereum also down slightly. Technical an...
